Study on Perioperative Coagulation and Outcomes in Patients With and Without Infective Endocarditis Undergoing Valve Surgery

What this Trial Is About

This research aims to compare patients with and without infective endocarditis who undergo valve surgery, as well as to evaluate patients with endocarditis treated either surgically or conservatively. The study focuses on understanding factors that may impact the care of these high-risk patients, including coagulation abnormalities, bleeding, and related complications. It will analyze how different pathogens influence disease severity and outcomes such as mortality and thromboembolic events. The study involves observing three groups patients with infective endocarditis undergoing valve surgery, those with infective endocarditis not requiring surgery, and patients undergoing valve surgery without endocarditis. Researchers will monitor coagulation factors, transfusion needs, heparin resistance, bleeding scores, and use predictive scores related to endocarditis and vasopressor-inotrope use. Comparisons will be made across these groups to better understand perioperative complications. Participants will be followed for up to one year to assess thromboembolic complications and mortality at 30 and 90 days, and one year after surgery or treatment. The study will collect data related to coagulation abnormalities during the first 24 hours after surgery and track pathogens and disease severity for up to 30 days. This detailed monitoring aims to optimize perioperative care for patients with infective endocarditis and valve disease.

The ENDOCARDITIS AUMC Data Collection